{
  "_id": "9682e262024749f39a5f17c766801ceb428a36370bd136aa4ab063f7fc4b32fe",
  "feed": "market-watch",
  "title": "Japan approves COVID antiviral pill as Pfizer, Merck alternative",
  "text": "<p>Osaka-based Shionogi filed in February for emergency approval for the drug, known as Xocova, in Japan. The health ministry panel said in July it needed to see results from a larger human trial because data submitted at the time didn't sufficiently show improvements in symptoms associated with Covid-19.</p><p>ALSO: China announces first COVID deaths in months and unveils restrictions in Beijing and Guangzhou</p><p>Shionogi's recent data showed that those who were given the drug once a day for five days recovered from symptoms including fever and cough 24 hours faster than those who received a placebo. Shionogi's pill is designed to be taken once a day without any additional medication.</p><p>While the drugs from Pfizer and Merck have been cleared for use for high-risk patients in the U.S., Shionogi's trials showed improvements among lower-risk patients, the company said.</p><p>A full version of this report can be found at WSJ.com</p><p>Japan approves COVID antiviral pill as Pfizer, Merck alternative</p>",
  "published": "2022-11-22T12:24:00.000Z",
  "tags": [
    {
      "id": "US58933Y1055",
      "nexusId": "10042334",
      "name": "Merck & Co., Inc.",
      "offsets": [
        {
          "start": 47,
          "end": 52
        },
        {
          "start": 714,
          "end": 719
        },
        {
          "start": 966,
          "end": 971
        }
      ]
    }
  ]
}